* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Practice slide 8 tafreeg 2
Discovery and development of non-nucleoside reverse-transcriptase inhibitors wikipedia , lookup
Discovery and development of integrase inhibitors wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Compounding wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Orphan drug wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
Psychopharmacology wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Drug design wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmacognosy wikipedia , lookup
Practice slide 8 tafreeg 2 1234 Last time we said that drug absorption interactions can happen due to many reasons: Changes in gastrointestinal PH Adsorption, chelation of medications Changes in gastrointestinal mortality Altered drug transport (p-glycoprotein) P-glycoprotein: are distributed in the intestines in the mucosal cells, it's an ATP dependent efflux pump which pumps the drug from mucosal cell to the intestinal lumen (prevents the absorption of the drug). * So if we gave something that inhibits the action of this P-glycoprotein, what happens to the drug concentration? - it will increase the drug absorption which sometimes could cause safety problems (toxicity) If we take P-glycoprotein substrate with P-glycoprotein inducer, in this case the effect of the drug from mucosal cells to intestinal lumen will increase therefore decreasing the drug absorption, which could cause efficacy problems we will have to give higher doses of the drug. Drugs that are called P-glycoprotein inducers and at the same time can be called Pglycoprotein inhibitors Amiodarone - EXAMPLES of drugs as P-glycoprotein inducers (Amiodarone, digoxin, diltiazem, statins, immunosuppressant's (cyclosporine and tacrolimus) - EXAMPLES of drugs as P-glycoprotein inhibitors ketoconazole, rifampil, immunosuppressant (cyclosporine) *ketoconazole: 1- mostly used topically .. rarely taken orally because of high D-D interaction 2- inhibitor for P-glycoprotein and CYP450. If we gave ketoconazole with digoxin, we have to decrease the digoxin dose because it's taken with P-glycoprotein inhibitor ketoconazole If we gave amiodarone with digoxin, we have to decrease the digoxin dose because in this case amiodarone works as a P-glycoprotein inhibitor. but if we gave amiodarone with ketoconazole, here amiodarone will work as a P-glycoprotein activator. If we gave carvedilol which is a P-glycoprotein inhibitor with diltiazem which is a Pglycoprotein substrate, we expect an elevation in diltiazem's concentrate Therefore, the toxicity has two reasons here: 1- Increase in the risk of hypotension (dynamic interaction) 2- Effect of P-glycoprotein (additive interaction) Also cyclosporine (immunosuppressant) works as a P-glycoprotein substrate and inhibitor (like amiodarone) *EXAMPLES of P-glycoprotein inducer: Ritonavir (antibiotic, rarely used) If we gave ritonavir with digoxin, what will happen? The absorption of digoxin will decrease which will reduce its efficacy, therefore we may have to increase digoxin dose. P-glycoprotein also exist in brain and kidneys, is important in these tissue to decrease the access of unwanted substrates to the blood. Digoxin for examples is eliminated in the kidneys with the help of P-glycoprotein but if we take digoxin with a P-glycoprotein inhibitor. this will increase absorption of digoxin, therefore increase the toxicity. Drug distribution interaction we will take in this topic about protein bindings: when the drug enters the body it either stays free or it binds to plasma proteins such as (albumin or α-glycoprotein) basic drugs usually bind to α-glycoprotein acidic drugs usually bind to albumin a great portion of the drugs are bound to proteins in the blood, but a few of them are found in free form. *the degree of protein binding is variable, rarely from less than 10% to 99% or greater The 1% left which is free always exist in equilibrium with the bound form, because there is constantly a portion goes through (metabolism + excretion) and another portion dissociate from proteins and become in the free form to achieve equilibrium. Physiology active form free form of the drug Problems is when we have a drug which is highly bound to plasma protein, administered with another drug which is also highly bound to plasma protein. There will be interaction between them, but if the second drug wasn't highly bound to plasma protein no interaction will occur between them. *EXAMPLES of highly bound to plasma protein ( >90%) : Warfarin, antiepileptic drug (phenytoin) The drug having the higher tendency to bind to plasma protein will displace the other bound drug and increase its toxicity. When a person takes 2 drugs, one is >90% protein bound, and the other is <90% protein bound there are no worries of displacements or interactions. Even if they happened there will be no significant clinical outcomes. WHY? 1- Because when the drug has wide therapeutic range it doesn't matter if a part of it was displaced and became free in the blood (no matter how much it was displaced there won't be a significant consequence and no toxicity will occur. (increase in concertation but without any toxicity) 2- The portion that become free won't stay in the blood, part of it will be excreted, another part will be metabolized or distributed to the site of action, therefore equilibrium will be formed again to maintain the free form concentration in the blood. Drugs that are protein bounded have longer half-lives. Sometimes we may have a delay between PD interaction (displacement) and PD interaction (response) Interactions of phenytoin and warfarin: Phenytoin will displace the warfarin increase conc of warfarin (PK interaction) and this increase the PD interaction but we won't see this interaction because the onset of warfarin is delayed. We measure the effect of warfarin through the life spam of clotting factors. We already have activated clotting factors but warfarin won't work on those but it works on the newly made clotting factors from the liver, therefore the already activated clotting factors won't reflect the effect of warfarin. So we have to wait for them to die and be eliminated from the body. After that we can see warfarin's effect on the new clotting factors. That's why it has a delayed onset of action 3-5 days (during this period the free form will be excreted, metabolized or distributed, therefore we won't see PD response) , and its full effect may take up to 2-3 weeks. When we have a drug like warfarin (has a delayed onset at action) even if PK interaction occurred there won't be a PD interaction. Between phenytoin and warfarin we see the effect of metabolism ( phenytoin increases the metabolism of warfarin by induction of CYP450 therefore we need to increase the dose ) not disturbtion ( the interaction that happened because of disturbtion resulting from the displacement on the protein ) so we have actual interaction between phenytoin and warfarin due to metabolism and the drug therapy needs to be modified. Altered drug transports: P-glycoprotein in the endothelial cells of brain capillaries is oriented to pump drug out of the cell and into the blood. Some drugs if entered the CNS will cause toxicity, but they don't enter because of the Pglycoprotein, that's why if we gave the drug with a P-glycoprotein inhibitor, it will enter the CNS and cause toxicity. *EXAMPLES: loperamicle (antidiarrheal by decreasing peristalsis) It works peripherally in the GIT and can't cross BBB (and that's what we want) If it enters the brain it will cause CNS toxicity and may even cause respiratory depression! Here we aren't talking about P-glycoprotein in the GIT that's why there won't be any effect on the efficacy, but safety is what we're concerned about. Drug metabolism interactions: All what's in the slide is required, but the doctor will say them briefly Elimination of drugs is mainly from the kidneys or the liver, but we have a very small portion that breaks down in the blood. Drugs that go straightly to the kidney such as hydrophilic drugs that go to the liver such as nonpolar compounds There are many drugs that don't go straightly to the kidney, but rather they go through the liver and get metabolized and become more polar. We have two types of metabolism: 1- Phase 1: oxidation / reduction / hydrolysis (to increase polarity of compound) 2- Phase 2: conjugation by (glucuronic acid / sulphate) Most of the interactions that happen due to metabolism are the result of inhibition or induction of CYP450 rather than the effect on the enzymes of glucoronate or sulfation. Most of the interactions that happen are phase 1 interactions mediated by CYP450. Enzyme inhibition: We need CYP450 either for a) activation of prodrugs b) elimination or inactivation of drugs if we have a prodrug that is given with a CYP450 inhibitor this will prevent the activation of the drug will affect the efficacy *EXMAPLES: prodrug – (clopidogrel) CYP450 inhibitor – (protein pump inhibitor (PPI)) If given together, we'll be concerned about thrombolysis (a form of clotting) But if we take an active form drug with CYP450 inhibitor, here we'll have a safety problem CYP450 inhibitor + prodrug efficacy issue CYP450 inhibitor + drug (active form ) safety issue ( increase conc of the drug ) The enzyme inhibitor can bind on the binding site of the enzyme (competitive inhibition) or can bind on a site other than the active site (non-competitive inhibition) The effect of the inhibition of the enzyme is fast. But in case of the induction of the enzyme the enzyme inducer works on the gene level (inc. expression of the enzyme by gene expression inc. response) needs time. That's why the effect of (enzyme inhibitors) are faster than (enzyme inducer) If we take a drug that works by gene expression as an (enzyme inducer) it needs 2-4 weeks to show an effect. If it was enzyme inhibitor faster interaction If it was enzyme inducer slow interaction 2-4 weeks Effect of the enzyme induction and enzyme inhibition on the AUC of the drugs: - The most representative thing for drug's concentration in the blood is AUC Dec. conc Dec. AUC Inc. conc inc. AUC - How we represent enzyme inhibition or induction? also here the effect of the enzyme inhibition on the AUC is more. Enzyme induction inc. CL Dec. AUC Enzyme inhibitor Dec. CL inc. AUC When the decrease In CL = 50% if enzyme inhibition AUC =100 Enzyme induction AUC = 33 *from slide 70 Slides 73, 74 ,75 aren't included Done by: Sahar Alazzam Christine Haddadin Danya Aljabrah Slide 8 tafreeg 3 Today we'll be talking about interactions due to change in excretion Excretion could be by the liver or kidney We have several things that can change the drugs excretion as a result of interacting with other drugs: abcd- Change in urinary PH Changes in active kidney tubule excretion Changes in kidney blood flow Biliary excretion and the entero-hepatic shunt Now in more details: 1- Changes in urinary PH This occurs if we have a drug that affects the urine PH and the other drugs is affected by the change of urine PH and this other drugs should be: a) Excreted uncharged in the urine: the number of drugs excreted uncharged in the urine is small and most drugs undergo metabolism and reach the urine as inactive metabolites. That's why we don't see this type of interaction very often. b) Ionized *EXAMPLES: salicylate and antacids antacids inc. PH of the urine so the excretion of salicylate will inc. because it becomes ionized. Therefore if we gave antacid with salicylate it's conc. In the body dec. because it will be excreted more readily. But if we gave salicylate with a drug that Dec. PH the excretion of salicylate will Dec. inc. it's plasma conc. inc. in its toxicity 2- Changes in active kidney tubule excretion: There are some drugs that are excreted in the urine by transporters (not by passive diffusion) In some cases 2 drugs are excreted from the same transporter, therefore the drug that overcomes the other and gets transported is excreted, and the other drug gets trapped in the body and it's plasma conc. Inc. -also this type of interactions isn't very important, because the number of drugs using this interaction is small. *EXAMPLES: probenecid (was been used for gout (hyperuricemia) in the past) With penicillin They both get transported by an active transporter in the kidney tubular and competition develops between penicillin and probenecid on the same transporter. Probenecid overcomes penicillin and gets excreted, while penicillin conc. Inc. in the blood causing potential toxicity (safety issue) 3- Changes in kidney blood flow: Many drugs affect kidney blood flow, potentially dec. it like NSAIDs (indometacir, diclofenac, naproxen. etc.) through affecting prostaglandins. NSAIDs dec. prostaglandins therefore decreasing kidney blood flow. For the drug to be affected by kidney blood flow it has to have a narrow therapeutic index. -an example of the drugs affected by using NSAIDs due to decreased kidney perfusion is (Lithium), because it mainly depends on the kidney perfusion for its excretion, plus it has a narrow therapeutic index. Therefore when the kidney perfusion is decreased, the conc. Of lithium in the blood inc. toxicity That's why patients taking lithium are prohibited from taking NSAIDs The number of drugs affected by this type of interaction is small, and they're: a- Have a narrow therapeutic index b- Their excretion is highly dependent on kidney perfusion 4- Biliary excretion and the entero-hepatic shunt Drugs which are affected by this interaction enter the entero-hepatic circulation which means the drug enters the liver, gets conjugated and removal with the bile back to the GIT, then it's supposed to exit with the feces. But what happens: the gut flora breaks down the conjugation bond, and it behaves like a normal drug which didn't get metabolized, so it gets absorbed and enters the liver again. This will inc. the drugs conc. In the blood, duration of the action and its half-life, therefore the effect of the drug will inc. with the entero-hepatic circulation. *how can we end this circulation? By reading the gut flora's activity by giving an antibacterial agent, therefore the drugs plasma conc. Will dec. so its half-life, and we'll have an efficacy issue because the effect of the drug will reduce. *EXAMPLES: oral contraception's (go through entero-hepatic circulation) when give with antibiotics they won't go through the entero-hepatic circulation and will be excreted in the feces without going back to the liver this will reduce the oral contraceptives efficacy and result is pregnancy. We're done with the four different types of interactions. When we want to decide the importance of the interactions, which one has a priory over the other and how to decide the clinical significant of different drug interactions: 1- Severity of the interaction: severe is more important than moderate and more than minor. - major life threating, permanent change Ex: statin with glimepiride rhabdomyolysis / warfarin with aspirin risk of bleeding - moderate deterioration of patient's status Ex: interaction causing hypokalemia - minor bothersome or little effect (considered minor when it has little consequences) Ex: using 2 antihypertensive agents 2- Reliability rating: likeability of the interaction to happen - excellent proven to occur in well controlled studies - good suggestive data, well controlled studies are lacking. they do exist but their content as studies are less than excellent - fair available documentation suggestive, good documentation for similar drug. there is documentation about interaction related to the drug's family not the drug itself - poor limited data but theoretically possible. like in case of drugs which have the same mechanism of action - unlikely poor documentation, lacks pharmacologic basis. no logic behind it. *the interaction is considered important and is called suspected interaction if its reliability rating is (excellent or good), and considered less important and is called possible interaction if its (fair, poor, or unlikely ) *** so depending on the documentation they can be classified to: a- Suspected interactions b- Possible interactions *** and generally we can prioritize these interactions into 5 categories: 1. 2. 3. 4. 5. Major / suspected Moderate / suspected Minor / suspected Major or moderate / possible Minor / possible Highest priority (most important) Lowest priority -pay attention that (suspected > possible) always -we've taken into consideration the severity of the interaction and reliability rating. 3- onset of interaction: to determine the speed of the interaction rapid (within 24 hrs or delayed (days to weeks) *EXAMPLES: verapamil makes enzyme induction This interaction has delayed onset because it happens on the gene transcription and translation level, therefore the interaction offered can be delayed, while in case of an enzyme inhibition interaction we need a fast intervention - Intervention: drug dosing adjustment, monitoring, therapy modifications ( switch or withdraw specific drugs ) 4-risk rating: is determine by C, D, X ..etc. C Benefit > risk -- that's why we do the monitoring D Benefit > or < risk -- we have to do therapy modification by adding, withdrawing, switching drugs or changing the dose or intensify the monitoring X risk > benefit -- avoid combination ((contraindicated)) Done by: Sahar alAzzam Christine Haddadin Danya Aljabrah